Can a drug extracted from seaweed treat Alzheimer's disease (commonly known as "Alzheimer's disease")? The new drug “Gal oligosaccharide diacid (GV-971)â€, which was developed by the Chinese Academy of Engineering academician Guan Huashi, has successfully completed Phase 3 clinical trials in July this year, bringing “gospel†to Alzheimer's patients worldwide. This new drug is derived from marine oligosaccharide molecules extracted from seaweed. The special structure and biological activity of marine natural products have special effects on the treatment of incurable diseases such as tumors and neurological diseases. This year, Guan Huashi, 79, is committed to marine drug research and development for nearly 40 years and is leading the research team to create a "blue drug store." They used super-calculation technology to solve the problem of "card neck" which is difficult to screen for new marine drugs, and applied traditional Chinese medicine theory to guide the development of new drugs. The “Blue Drugstore†is expected to generate a steady stream of innovations. Marine bearer treatment, new hope of incurable diseases Humans mainly live on land, and the drugs they develop are mainly derived from land. However, if they are used more, they may develop drug resistance. As a result, people turned their attention to the vast ocean. Lv Zhihua, deputy dean of the School of Medicine, Ocean University of China, introduced that in order to survive and reproduce in the deep sea environment, deep-sea creatures such as seaweed, microorganisms and fish have evolved unique genes, which are cold-resistant, heat-resistant and high-pressure resistant, resulting in strange structures and activities. A variety of marine natural products, which provide important structural information for the development of modern innovative drugs, and are an important source of drug lead compounds for human major diseases such as cancer, cardiovascular and cerebrovascular diseases, immune diseases, and nervous system diseases. Guan Huashi told reporters that humans have discovered 35,000 marine natural products, more than half of which are biologically active, far more biologically active than the natural products of animals and plants on land, and there are many unknown marine natural products. The ocean can provide a large number of drug lead compounds. But so far, only 13 new marine drugs have been on the market, and the marine biomedical industry has great potential. Among the 13 new marine drugs that have been listed, one of China has contributed to it, which is the sodium alginate (PSS) developed by Guan Huashi in 1985. It is a polysaccharide sulfate drug extracted from natural seaweed. Prevention and treatment of ischemic heart and cerebrovascular diseases. The reporter learned in the interview that the reason why the successful listing of marine drugs is rare is that the acquisition of marine organisms is difficult, which requires the support of scientific research vessels and advanced deep-sea sampling equipment. Second, the research and development is difficult, and the marine natural products are complex in structure and extremely low in content. Large-scale preparation is difficult; third, the development process is long, from natural products to active compounds, lead compounds, drug candidates, to phase III clinical trials, it takes a lot of manpower, material resources, financial resources and time, any problem will be a problem Let the new drug "dead". After entering the 21st century, the development and listing speed of marine drugs has accelerated significantly. In the past decade, eight marine drugs have been approved for marketing by the US FDA (Food and Drug Administration) or the European Union EMEA (European Drug Evaluation Agency). By 2016, the global market for marine medicines reached 8.6 billion US dollars, which has become an important pole in the development of the blue economy. "In recent years, with the continuous development of basic research in the fields of ocean, chemistry, biology, medicine, etc., marine equipment technology has been continuously upgraded, and marine biomedicine has entered a new stage of deep-scale development." Guan Huashi said. It is understood that countries around the world, especially the United States, Japan and the European Union, have formulated corresponding plans and invested heavily in the development of marine living resources. Marine medicine has become a hot spot in the international pharmaceutical field. Screening difficult and super-computing technology to break through the "card neck" problem Since last year, Guanhua's research team has been committed to building China's “blue drug storehouseâ€. It has initially established a marine biological resource bank and a marine drug-related information base. In the future, it will focus on the development of marine small molecule drugs, marine sugar drugs, and marine Chinese medicines. And marine life functional products. In the development of “Blue Medicine Libraryâ€, the Chinese Ocean University Medical College led by Guan Huashi is engaged in basic research, Qingdao Marine Biomedical Research Institute is engaged in industrialization, clinical trials and marketing promotion are handed over to cooperative enterprises; Qingdao Marine Biomedical Research The hospital also established a “China Blue Medicine Library Development Fund†with a total scale of 5 billion yuan with Zhengda Pharmaceutical (Qingdao) Co., Ltd., which initially formed a complete chain of marine drug research and development. Yang Jinbo, chief scientist of Qingdao Marine Biomedical Research Institute, said that marine biological sample resources are very precious, and the content of natural products is extremely small, and often only very limited experiments can be done. Large-scale manual preparation is generally not performed until it is determined that it has medicinal value. Because of the complex structure of marine natural products, manual preparation is difficult and costly. Once there is no medicinal value, large-scale preparation of products is wasted. In this case, the accuracy of screening for marine drugs is less than 20%. In the process of creating a “blue drug storehouseâ€, Qingdao Marine Biomedical Research Institute is committed to using the super-calculation technology to solve the “card neck†problem of difficult screening of marine drugs. They have built a three-dimensional structure database containing about 30,000 marine natural products, and have initially constructed a database of all drug molecular targets published by the US Food and Drug Administration. Experts say that in the past, it was a blind test of trace marine natural products for specific diseases. The application of supercomputer technology is big data calculation and matching. This technology will increase the accuracy of marine drug screening from less than 20% to more than 60%. The reporter learned that with the iterative upgrade of this technology, reverse drug development can be carried out in the future: that is, according to the molecular target data of the drug, the structure of the compound that can treat the disease can be automatically generated, and then the new compound can be artificially prepared on a large scale, and then the new drug development can be carried out. And clinical trials. Applying traditional Chinese medicine theory to guide the development of new marine drugs Guan Huashi told reporters that in order to treat Alzheimer's disease, more than 130 drugs have been tested in 16 countries. The success of GV-971 is due to the research and development under the guidance of TCM theory. , multi-target, synergistic results. This drug not only acts on the hippocampus of the head, but also regulates the imbalance of the intestinal flora and remodels the body's immune homeostasis, thereby reducing neuroinflammation in the brain and preventing the progression of Alzheimer's disease. Experts said that GV-971's novel mode of action and unique multi-target action characteristics have opened up a new path for Alzheimer's disease drug development, and are expected to lead the new wave of marine sugar drug research and development, promote Chinese medicine theory and marine innovative drug research and development. Deep integration has far-reaching significance for enhancing China's international status in the field of innovative drug research. "Analysis of the structural characteristics of marine drugs developed at home and abroad, it is not difficult to find that sugar-based marine drugs account for a large proportion, sodium alginate (PSS) and GV-971 are marine sugar drugs, BG136 and TGC161 It is also a sugar drug." Yu Guangli, dean of the School of Medicine, Ocean University of China, said, "Marine sugar drugs are an important direction for our efforts." Multiple scientific research forces In addition to the research team of Ocean University of China led by Guan Huashi, there are many research forces in China dedicated to the research and development of marine biomedicine, including the Third Institute of Ocean Resources of the Ministry of Natural Resources, the Institute of Oceanology of the Chinese Academy of Sciences, and the research institutes and universities of Sun Yat-sen University. They are all important forces in the development of marine medicine. The research team led by Yang Xianwen, a researcher at the Third Institute of Oceanography of the Ministry of Natural Resources, is relying on the China Marine Microbial Culture Collection Management Center to conduct research on more than 20,000 deep-sea microbes in the reservoir. In collaboration with a pharmaceutical company, anti-tumor lead compounds were found in deep-sea microbes against five cancers, including liver cancer and cervical cancer. At present, they have completed the excavation of more than 700 microorganisms, and found a lead compound with good potential for development and application. The research team led by Shi Dayong, a researcher at the Institute of Oceanology of the Chinese Academy of Sciences, is working hard to treat diabetes. Protein tyrosine phosphatase 1B (PTP1B), an important negative regulator of insulin signaling pathway, has become an attractive target for the treatment of type 2 diabetes. “We have carried out research on the isolation, identification and structural optimization of 13 active ingredients of seaweed and constructed a biological activity information base of bromine compounds.†Shi Dayong said that they screened the in vitro activity of enzyme and level of bromine compound library and found that There are 12 compounds with strong PTP1B inhibitory activity. Among them, the compound "Hprenor" which is obtained by structural modification with natural bromide BPN is not only novel in structure, but also has stronger inhibitory activity against PTP1B, and can be used for treating type 2 diabetes and obesity. The proportion of original innovative drugs in the number of drugs in China has been low, and marine biomedicine is a new opportunity for China to catch up with the international level of original innovative drugs. Experts pointed out that the basic theoretical research on the chemical, biological, ecological and pharmacological aspects of marine life in China is still relatively weak. "Domestic marine drug research mostly stays in the research and development stage of primary metabolites. It should pay attention to the basic research of marine organisms, cross-disciplinary research, and focus on the development of new drug lead compounds with important physiological activities and drug preparation prospects." Shi Dayong said. Whether it is project establishment, investment, drug development, sales promotion, enterprises should be the main body of marine drug research and development. At present, most of China's research work on marine biomedicine is done by universities and research institutes. Experts believe that some marine drug research and development projects with transformation prospects in China, despite their good scientific research foundation, have been delayed due to lack of necessary industrialization research and pilot experiments. Universities and research institutes have the ability to develop science and technology, but they are often less sensitive to the market. They should speed up the cooperation between industry, universities and research institutes and turn good results into new drugs. Guan Huashi suggested that a cooperative mechanism for the mutual benefit and win-win of marine drug development should be formed nationwide. For example, the implementation of the “Blue Medicine Library†big science plan will bring together the best marine scientific research forces in the country, strengthen the construction of engineering and industrial development platforms, and let the top teams work together to innovate and form the whole of marine drug development. Chain. Source: Economic Information low speed handpiece,dental low speed handpiece,low speed dental handpiece Foshan Ja Suo Medical Device Co., LTD , https://www.fjoralinstrument.com
"We will rely on the super-computing resources of Qingdao, Jinan and Wuxi and the established database resources to compare and calculate the three-dimensional structure of marine products with the molecular target data of drugs, just like the comparison of 'key' and 'lock' And calculation." Yang Jinbo said.
Following the treatment of new drugs for Alzheimer's disease, the team of Guan Huashi has two new marine drugs coming soon: BG136 for colon cancer and TGC161 for anti-HPV virus, of which BG136 is a natural product extracted from Antarctic ice algae. Cheng, intends to declare clinical at the end of next year.
Chinese scientists explore to open the "blue drug library" password
:2018-10-18